CLCA2 as a p53-inducible senescence mediatorspi

Neoplasia

Volumn 14, Issue 2, 2012, Pages 141-149

  Tanikawa, Chizu ^a   Nakagawa, Hidewaki ^b   Furukawa, Yoichi ^a   Nakamura, Yusuke ^a   Matsuda, Koichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA ACTIN; CHLORIDE CHANNEL; CHLORIDE CHANNELS ACCESSORY 2; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL PROLIFERATION; COLORECTAL CANCER; DNA MICROARRAY; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SENESCENCE; WESTERN BLOTTING;

EID: 84858068411     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111700     Document Type: Article

References (59)

1. Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M, and Beroud C (2006). Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12, 62-69.
2. Vogelstein B, Lane D, and Levine AJ (2000). Surfing the p53 network. Nature 408, 307-310.
3. AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 62, 2883-2889.
4. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49.
5. el-Deiry WS (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8, 345-357.
6. Nakamura Y (2004). Isolation of p53-target genes and their functional analysis. Cancer Sci 95, 7-11.
7. Tanikawa C, Furukawa Y, Yoshida N, Arakawa H, Nakamura Y, and Matsuda K (2009). XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene 28, 3081-3092.
8. AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862.
9. RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 5, 216-223.
10. Tanikawa C, Ueda K, Nakagawa H, Yoshida N, Nakamura Y, and Matsuda K (2009). Regulation of protein citrullination through p53/PADI4 network in DNA damage response. Cancer Res 69, 8761-8769.
11. Tanikawa C, Ri C, Kumar V, Nakamura Y, and Matsuda K (2010). Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway. Mol Cancer Res 8, 855-863.
12. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, and Matsuda K (2008). CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27, 1562-1571.
13. Tanikawa C, Espinosa M, Suzuki A, Masuda K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y, and Matsuda K (2012). Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun 3, 676.
14. INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346.
15. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J, and Helin K (2009). The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23, 1171-1176.
16. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203-211.
17. INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 5, 379-389.
18. Wu J, Xue L, Weng M, Sun Y, Zhang Z, Wang W, and Tong T (2007). Sp1 is essential for p16 expression in human diploid fibroblasts during senescence. PLoS One 2, e164.
19. Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene 26, 7665-7674.
20. INK4a-mediated premature senescence. J Appl Physiol 100, 988-995.
21. Gil J and Peters G (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7, 667-677.
22. Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30, 2087-2097.
23. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, and Donehower LA (1993). In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8, 2457-2467.
24. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, and Lowe SW (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
25. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, et al. (2002). p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53.
26. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
27. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637.
28. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436, 642.
29. Campisi J (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522.
30. Herbig U, Jobling WA, Chen BP, Chen DJ, and Sedivy JM (2004). Telo-mere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 14, 501-513.
31. Wang YA, Elson A, and Leder P (1997). Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 94, 14590-14595.
32. Walia V, Ding M, Kumar S, Nie D, Premkumar LS, and Elble RC (2009). hCLCA2 is a p53-inducible inhibitor of breast cancer cell proliferation. Cancer Res 69, 6624-6632.
33. 2+-activated chloride channel CLCA2. Cancer Res 59, 5488-5491.
34. Li X, Cowell JK, and Sossey-Alaoui K (2004). CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Oncogene 23, 1474-1480.
35. Rovillain E, Mansfield L, Caetano C, Alvarez-Fernandez M, Caballero OL, Medema RH, Hummerich H, and Jat PS (2011). Activation of nuclear factor-κ B signalling promotes cellular senescence. Oncogene 30, 2356-2366.
36. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, and Nakamura Y (2006). Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 29, 567-575.
37. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S, et al. (1993). Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8, 3313-3322.
38. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, et al. (2004). Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64, 5963-5972.
39. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92, 9363-9367.
40. Beckley JR, Pauli BU, and Elble RC (2004). Re-expression of detachment-inducible chloride channel mCLCA5 suppresses growth of metastatic breast cancer cells. J Biol Chem 279, 41634-41641.
41. Elble RC and Pauli BU (2001). Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium. J Biol Chem 276, 40510-40517.
42. Yamabuki T, Daigo Y, Kato T, Hayama S, Tsunoda T, Miyamoto M, Ito T, Fujita M, Hosokawa M, Kondo S, et al. (2006). Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 28, 1375-1384.
43. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, et al. (2005). Predicting response to metho-trexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11, 2625-2636.
44. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K, and Nakamura Y (2004). Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25, 797-819.
45. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, et al. (2008). A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146-155.
46. Reshkin SJ, Bellizzi A, Albarani V, Guerra L, Tommasino M, Paradiso A, and Casavola V (2000). Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem 275, 5361-5369.
47. Rich IN, Worthington-White D, Garden OA, and Musk P (2000). Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood 95, 1427-1434.
48. + exchanger activity and aging. Eur Arch Psychiatry Clin Neurosci 247, 275-277.
49. Xiong Z-G, Pignataro G, Li M, Chang S-Y, and Simon RP (2008). Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol 8, 25-32.
50. Elble RC, Walia V, Cheng HC, Connon CJ, Mundhenk L, Gruber AD, and Pauli BU (2006). The putative chloride channel hCLCA2 has a single C-terminal transmembrane segment. J Biol Chem 281, 29448-29454.
51. Kriegler M, Perez C, DeFay K, Albert I, and Lu SD (1988). A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53, 45-53.
52. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, and Spies T (1999). Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729.
53. Groh V, Wu J, Yee C, and Spies T (2002). Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738.
54. Ito K, Okamoto I, Araki N, Kawano Y, Nakao M, Fujiyama S, Tomita K, Mimori T, and Saya H (1999). Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of β-catenin from cell-cell contacts. Oncogene 18, 7080-7090.
55. Krtolica A, Parrinello S, Lockett S, Desprez PY, and Campisi J (2001). Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 98, 12072-12077.
56. Ren XH, Peng XD, Wu XP, Liao EY, and Sun ZQ (2008). Association between serum soluble membrane type matrix metalloproteinase-1 (MT1-MMP) levels and bone mineral density, and biochemical markers in postmenopausal women. Clin Chim Acta 390, 44-48.
57. Yang SC, Chiang CK, Hsu SP, and Hung KY (2008). Relationship between interdialytic weight gain and nutritional markers in younger and older hemodi-alysis patients. J Ren Nutr 18, 210-222.
58. Thompson HJ and Voss JG (2009). Health- and disease-related biomarkers in aging research. Res Gerontol Nurs 2, 137-148.
59. Bekaert S, De Meyer T, and Van Oostveldt P (2005). Telomere attrition as ageing biomarker. Anticancer Res 25, 3011-3021.